Powder: -20°C for 3 years | In solvent: -80°C for 1 year
(±)-Carnitine chloride (Monocamin) 有D 和L 两种异构体。其中 L-carnitine 在脂肪酸的 β-氧化中起重要作用,也具有抗氧化作用和抗炎活性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
10 g | ¥ 137 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 228 | 现货 |
产品描述 | (±)-Carnitine chloride (Monocamin) is a quaternary ammonium compound biosynthesized from the amino acids lysine and methionine. |
体外活性 | The main effect of L-carnitine is to shuttle long-chain fatty acids across the inner mitochondrial membrane. After L-carnitine and acyl-CoA become acyl-carnitine by activation of carnitine palmitoyl transferase (CPT)-I, the transported acyl-carnitine is changed into acyl-CoA by CPT-II in the mitochondria matrix. Palmitoyl-CoA-induced mitochondrial respiration is increased by L-carnitine treatment, and then is accelerated by the presence of ADP. This acceleration is induced by treatment with L-carnitine in a concentration-dependent manner, and is saturated at 5 mM L-carnitine[1]. Pretreatment with L-carnitine augments Nrf2 nuclear translocation, DNA binding activity and heme oxygenase-1 (HO-1) expression in Water2-treated HL7702 cells. L-carnitine protects HL7702 cells against Water2-induced cell damage through Akt-mediated activation of Nrf2 signaling pathway[2]. |
体内活性 | L-carnitine is found to down-regulate the ubiquitin proteasome pathway and increase IGF-1 concentrations in animal models. L-carnitine administration for 2 weeks of hindlimb suspension alleviates the decrease in weight and fiber size in the soleus muscle. Moreover, L-carnitine suppresses atrogin-1 mRNA expression, which has been reported to play a pivotal role in muscle atrophy[3]. Simultaneous treatment with L-carnitine attenuates the renal fibrosis (which correlated with a reduction of plasma TGF-β1 levels) and the pro-oxidative and proinflammatory status reported in L-NAME groups, with a concomitant increase in the expression of PPAR-γ[4]. |
激酶实验 | Mitochondria (0.6 mg protein/mL) are incubated in 2.5 mM Hepes (pH7.4) containing 225 mM mannitol, 75 mM sucrose and 100 μM ethylene glycol tetraacetic acid (EGTA) with or without 5 mM L-carnitine at 25°C. To measure oxygen uptake, 10 min after inorganic phosphate (Pi) 4 mM are added, the mitochondria are treated with palmitoyl-CoA (50 μM) and then ADP is added (200 μM). Oligomycin (5 μM) and rotenone (10 μM) are added 3-4 min after the ADP treatment. HPG (0-10 mM), which can specifically inhibit carnitine palmitoyl transferase (CPT)-I activity in the mitochondria, is added in the Hepes medium before incubation of the mitochondria[1]. |
别名 | Monocamin, DL-Carnitine HCl, Bicarnesine, 混旋肉碱盐酸盐, DL-Carnitine chloride |
分子量 | 197.66 |
分子式 | C7H15NO3·HCl |
CAS No. | 461-05-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 37 mg/mL (187.2 mM)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 45 mg/mL (227.66 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
H2O / DMSO | 1 mM | 5.0592 mL | 25.296 mL | 50.5919 mL | 126.4798 mL |
5 mM | 1.0118 mL | 5.0592 mL | 10.1184 mL | 25.296 mL | |
10 mM | 0.5059 mL | 2.5296 mL | 5.0592 mL | 12.648 mL | |
20 mM | 0.253 mL | 1.2648 mL | 2.5296 mL | 6.324 mL | |
50 mM | 0.1012 mL | 0.5059 mL | 1.0118 mL | 2.5296 mL | |
100 mM | 0.0506 mL | 0.253 mL | 0.5059 mL | 1.2648 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
(±)-Carnitine chloride 461-05-2 Immunology/Inflammation Metabolism NF-Κb Reactive Oxygen Species DL-Carnitine Chloride (±) Carnitine chloride inhibit Inhibitor Monocamin DL-Carnitine HCl Bicarnesine (±)Carnitine chloride DL-Carnitine 混旋肉碱盐酸盐 DL-Carnitine chloride Carnitine Chloride (±)-Carnitine inhibitor